NASDAQ:PIRS

Pieris Pharmaceuticals - PIRS Stock Forecast, Price & News

$0.99

-0.01 (-1.00%)

(As of 12/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.95
▼
$1.00
50-Day Range: $0.94
▼
$1.19
52-Week Range: $0.92
▼
$4.08

Volume: 147,024 shs
Average Volume: 372,527 shs
Market Capitalization: $73.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Pieris Pharmaceuticals (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

November 23, 2022 | finance.yahoo.com

Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference

November 9, 2022 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

November 9, 2022 | finance.yahoo.com

Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

November 2, 2022 | msn.com

Recap: Pieris Pharmaceuticals Q3 Earnings

November 2, 2022 | seekingalpha.com

Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Call Transcript

November 2, 2022 | finance.yahoo.com

Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 2, 2022 | finance.yahoo.com

Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates

November 1, 2022 | finance.yahoo.com

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

October 26, 2022 | finance.yahoo.com

Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022

September 12, 2022 | finance.yahoo.com

Shareholders in Pieris Pharmaceuticals (NASDAQ:PIRS) are in the red if they invested a year ago

September 8, 2022 | finance.yahoo.com

Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 25, 2022 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

August 24, 2022 | finance.yahoo.com

Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate

August 24, 2022 | finance.yahoo.com

Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

August 12, 2022 | nasdaq.com

Pieris Pharmaceuticals (NASDAQ:PIRS) Will Have To Spend Its Cash Wisely

August 10, 2022 | finance.yahoo.com

One Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analyst Is Reducing Their Forecasts For This Year

August 6, 2022 | seekingalpha.com

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2022 | finance.yahoo.com

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 28, 2022 | finance.yahoo.com

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

July 14, 2022 | finance.yahoo.com

Here's Why We're Not Too Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Situation

June 18, 2022 | seekingalpha.com

PIRS Pieris Pharmaceuticals, Inc.

June 2, 2022 | finance.yahoo.com

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

May 18, 2022 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

May 18, 2022 | finance.yahoo.com

Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Company Calendar

Last Earnings: 11/02/2022
Today: 12/05/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PIRS
CUSIP: N/A
CIK: 1583648
Web: www.pieris.com
Phone: (857) 246-8998
Fax: 49-8161-141-1444
Employees: 124
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,740,000.00
Net Margins: -121.78%
Pretax Margin: -121.78%
Return on Equity: -75.31%
Return on Assets: -27.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.34
Quick Ratio: 2.34

Sales & Book Value

Annual Sales: $31.42 million
Price / Sales: 2.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.70 per share
Price / Book: 1.41

Miscellaneous

Outstanding Shares: 74,406,000
Free Float: 68,974,000
Market Cap: $73.59 million
Optionable: Optionable
Beta: 1.01

Key Executives

Mr. Stephen S. Yoder J.D. (Age 46)
CEO, Pres & Director
Comp: $834.16k

Dr. Hitto Kaufmann Ph.D. (Age 51)
Sr. VP & Chief Scientific Officer
Comp: $520.29k

Mr. Thomas Bures (Age 48)
Sr. VP & CFO

Maria Kelman
Exec. Director of Investor Relations

Mr. Ahmed S. Mousa J.D. (Age 37)
Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec.

Mr. Frank Vollmering
VP of HR

Dr. Christine Rothe Ph.D.
VP and Head of Early Stage Project Leadership & Data Science

Dr. Shane Olwill Ph.D. (Age 46)
Sr. VP & Chief Devel. Officer

Mr. Prompong Chaikul (Age 35)
Chief Supply Chain Officer

Dr. Gordon Otto M.D.
Ph.D., Head of Clinical Devel. Oncology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PIRS Stock - Frequently Asked Questions

How have PIRS shares performed in 2022?: Pieris Pharmaceuticals' stock was trading at $3.78 at the start of the year. Since then, PIRS shares have decreased by 74.0% and is now trading at $0.9845.
View the best growth stocks for 2022 here.
When is Pieris Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our PIRS earnings forecast.
How were Pieris Pharmaceuticals' earnings last quarter?: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its earnings results on Wednesday, November, 2nd. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The biotechnology company had revenue of $5.37 million for the quarter, compared to analysts' expectations of $4.51 million. Pieris Pharmaceuticals had a negative net margin of 121.78% and a negative trailing twelve-month return on equity of 75.31%.
What other stocks do shareholders of Pieris Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).

What is Pieris Pharmaceuticals' stock symbol?: Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
Who are Pieris Pharmaceuticals' major shareholders?: Pieris Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Lynx1 Capital Management LP (4.72%), Marshall Wace LLP (3.28%), Platinum Investment Management Ltd. (1.64%), Renaissance Technologies LLC (0.98%), Jacobs Levy Equity Management Inc. (0.53%) and Connor Clark & Lunn Investment Management Ltd. (0.18%). Insiders that own company stock include Aquilo Capital Management, Llc, Shane Olwill and Tim Demuth.
View institutional ownership trends.
How do I buy shares of Pieris Pharmaceuticals?: Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pieris Pharmaceuticals' stock price today?: One share of PIRS stock can currently be purchased for approximately $0.98.
How much money does Pieris Pharmaceuticals make?: Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $73.25 million and generates $31.42 million in revenue each year. The biotechnology company earns $-45,740,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.
How many employees does Pieris Pharmaceuticals have?: The company employs 124 workers across the globe.
How can I contact Pieris Pharmaceuticals?: Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444.

This page (NASDAQ:PIRS) was last updated on 12/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial